Logo image
Ethical challenges for a new generation of early-phase pediatric gene therapy trials
Journal article   Open access   Peer reviewed

Ethical challenges for a new generation of early-phase pediatric gene therapy trials

Alexander A Iyer, Dimah Saade, Diana Bharucha-Goebel, A Reghan Foley, Gilberto 'Mike' Averion, Eduardo Paredes, Steven Gray, Carsten G Bönnemann, Christine Grady, Saskia Hendriks, …
Genetics in medicine, Vol.23(11), pp.2057-2066
11/2021
DOI: 10.1038/s41436-021-01245-3
PMID: 34234300
url
https://doi.org/10.1038/s41436-021-01245-3View
Published (Version of record) Open Access

Abstract

After decades of setbacks, gene therapy (GT) is experiencing major breakthroughs. Five GTs have received US regulatory approval since 2017, and over 900 others are currently in development. Many of these GTs target rare pediatric diseases that are severely life-limiting, given a lack of effective treatments. As these GTs enter early-phase clinical trials, specific ethical challenges remain unresolved in three domains: evaluating risks and potential benefits, selecting participants fairly, and engaging with patient communities. Drawing on our experience as clinical investigators, basic scientists, and bioethicists involved in a first-in-human GT trial for an ultrarare pediatric disease, we analyze these ethical challenges and offer points to consider for future GT trials.
Child Clinical Trials as Topic - ethics Genetic Therapy - ethics Humans Treatment Outcome

Details

Logo image